Key facts
- This page summarizes Susan Mahony's Form 4 filing for Zymeworks Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 07 May 2021, 20:45.
Susan Mahony - 06 May 2021 Form 4 Insider Report for Zymeworks Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 06 May 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 May 2021, 20:45:28 UTC
- Next SEC filing
- 24 May 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel Dex, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Susan Mahony filed Form 4 for Zymeworks Inc. on 07 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZYME
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +9,000
- Change %
- Price
- $0.000000
- Shares after
- 9,000
- Date
- 06 May 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 9,000
- Exercise price
- $29.49
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Stock options vest on date of next annual general meeting following grant date of May 6, 2021.